BGM1812
BGM1812, dual amylin and calcitonin receptor agonist
Written by Aaron CuhaReviewed Sep 2026
A dual amylin and calcitonin receptor agonist from BrightGene, derived from the structure of petrelintide, with one medicinal chemistry paper reporting animal and in vitro results and two phase 1 trials recruiting in China and the United States. No human data have been published.
Overview
BGM1812 is a peptide developed by BrightGene Bio-Medical Technology in Suzhou, China, as a dual amylin and calcitonin receptor agonist (DACRA) for obesity. Its only publication is the discovery paper in the Journal of Medicinal Chemistry (July 2025), which describes it as the product of three rounds of structure-guided modification starting from petrelintide, the long-acting amylin analogue then in phase 2, using molecular dynamics simulations to compensate for the absence of structure-activity data. Two methylation strategies produced a compound the authors report as having improved half-life, stability and solubility and enhanced efficacy in both in vitro and in vivo studies. The abstract gives no species, group sizes or effect sizes, and the paper is medicinal chemistry, not a pharmacology study designed to characterise a drug.
Two phase 1 trials are registered and both were listed as recruiting on 11 September 2026. NCT07224399 is a single-centre, double-blind, placebo-controlled, dose-escalation study of single and multiple subcutaneous doses in normal to overweight or obese but otherwise healthy adults in the United States, started 9 October 2025, estimated 60 participants, primary completion May 2026. NCT07294235 is a randomised, double-blind, placebo-controlled single and multiple dose study in healthy and non-diabetic overweight or obese Chinese participants, started 5 December 2025, estimated 60 participants, primary completion March 2026. Both list adverse events as the primary outcome. Both primary completion dates had passed at the time of writing while the status still read recruiting, and neither record had been updated since December 2025. No results have been posted.
There are no human data. Any statement about BGM1812's weight effect is, at most, an animal result reported in a chemistry paper. It is investigational and not approved anywhere.
Mechanism of action
Amylin receptors are formed from the calcitonin receptor together with receptor activity modifying proteins; a dual amylin and calcitonin receptor agonist activates both the amylin receptor complexes and the calcitonin receptor alone. In animals, DACRAs reduce food intake and body weight through hindbrain satiety circuits and slow gastric emptying, and the field's working hypothesis, reviewed in 2026, is that calcitonin receptor engagement may increase efficacy while also influencing nausea and aversion. Whether that is true for BGM1812 in people is unknown. The discovery paper reports that BGM1812 was designed from petrelintide's structure with methylation at positions chosen by molecular dynamics modelling, and that it showed improved half-life, stability and solubility and greater efficacy than its parent in vitro and in vivo. The abstract does not state the species, the model, the doses or the magnitude of any effect. No pharmacokinetic value, receptor potency or animal weight loss figure is available in a form this profile can report.
Human evidence
None published. Two phase 1 safety studies of about 60 people each were listed as recruiting in September 2026 and have posted no results. No person's response to BGM1812 has been reported anywhere.
What this does not tell you: Everything. The compound's pharmacology in people, its tolerability, its half-life and any weight effect are unknown. The only data are animal and in vitro results summarised without numbers in a chemistry paper by the company that owns it. Petrelintide's phase 1 results describe the parent molecule, not this one.
Reading the research record
BGM1812 is at the earliest stage a compound can be and still have a clinical trial number. The record is a single industry-authored medicinal chemistry paper and two registry entries, which is normal for a compound that entered phase 1 in late 2025. The paper's framing is worth reading carefully: it presents BGM1812 as an optimisation of petrelintide, a competitor's molecule whose phase 1 data are now published, and it builds its case on modelling rather than on measured receptor structures because, as the authors say, structure-activity data for the class were lacking.
Both trials' registered primary completion dates had passed at the time of writing while their status still read recruiting and neither record had been updated in nine months. That is common for small phase 1 studies and is not evidence of a problem, but it means the registry cannot currently tell a reader whether the trials are ongoing, finished or delayed. When results appear they will be safety and pharmacokinetic data from around 120 healthy or overweight volunteers, not efficacy data. Until then the accurate description of BGM1812's weight effect is an animal result whose size has not been published.
The evidence, charted
Fig. 1 · evidence composition
3of 5 citations (60%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2025 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2025
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Medicinal chemistry paper from BrightGene. BGM1812 was derived from petrelintide through three rounds of structure-based modification and molecular dynamics guided methylation. The abstract reports improved half-life, stability and solubility and enhanced efficacy in vitro and in vivo without stating species, doses or effect sizes. The only publication on the compound; industry authored.
Journal of Medicinal Chemistry - Human2025
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
Phase 1, single-centre, double-blind, placebo-controlled dose escalation, United States. Sponsor BrightGene. Started 9 October 2025, estimated 60 participants, primary completion 15 May 2026. Primary outcome: number of treatment adverse events. Listed as recruiting, last updated November 2025; no results posted.
ClinicalTrials.gov - Human2025
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
Phase 1, randomised, double-blind, placebo-controlled, single and multiple doses, China. Sponsor BrightGene. Started 5 December 2025, estimated 60 participants, primary completion 2 March 2026. Primary outcome: participants with adverse events and serious adverse events. Listed as recruiting, last updated December 2025; no results posted.
ClinicalTrials.gov - Human2026
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
Petrelintide, the parent scaffold from which BGM1812 was derived, in randomised placebo-controlled phase 1 trials: half-life about 10 days, weight reduction up to 8.6 percent after 16 weeks of weekly dosing, nausea in 16.7 to 33.3 percent against 16.7 percent on placebo. These are petrelintide data and say nothing directly about BGM1812.
Diabetes, Obesity and Metabolism - Review2026
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Class review of long-acting amylin and dual amylin and calcitonin receptor agonists in clinical development. Its abstract does not mention BGM1812.
Peptides
Frequently asked questions
What is BGM1812?
A dual amylin and calcitonin receptor agonist peptide from BrightGene, a Chinese company, designed by modifying the structure of petrelintide. It is in phase 1 trials in China and the United States and is not approved anywhere.
Does it cause weight loss in people?
Unknown. No human data have been published. The two phase 1 trials measure safety and adverse events as their primary outcomes and have posted no results. The only efficacy claim is an animal result in the discovery paper, which does not give the species, dose or size of the effect in its abstract.
How does it relate to petrelintide?
The discovery paper describes BGM1812 as derived from petrelintide's structure through three rounds of modification intended to improve potency, half-life, stability and solubility. Petrelintide itself has published phase 1 data showing up to 8.6 percent weight loss at 16 weeks; those data belong to petrelintide and do not transfer to BGM1812.